Quidelortho Corporation (DE:QL1A)
NASDAQ:QL1A
QL1A Stock Chart & Stats
€10.31
-€1.00(-2.20%)
At close: 4:00 PM EST
€10.31
-€1.00(-2.20%)
Day’s Range― - ―
52-Week Range€8.22 - €30.40
Previous CloseN/A
Volume44.00
Average Volume (3M)2.00
Market Cap
€854.77M
Enterprise Value€3.62B
Total Cash (Recent Filing)€140.40M
Total Debt (Recent Filing)€2.87B
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Jul 30, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.85
Shares Outstanding68,190,990
10 Day Avg. Volume0
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.03
Price to Sales (P/S)0.73
P/FCF Ratio-23.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.44Price Target Upside1.27% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)1.58
Revenue Forecast (FY)€2.33B
Bulls Say, Bears Say
Bulls Say
Consumables-driven Recurring Revenue And Diversified MixA large non‑respiratory base (≈$552M of $620M Q1 revenue) shows the business relies on recurring consumables and lab demand, which supports predictable pull‑through revenue independent of respiratory seasonality and underpins durable consumables cash flow as installed instruments run assays over time.
Lex Acquisition Expands Point-of-care Molecular PlatformLex adds an ultrafast molecular POC instrument and a clear pathway to durable instrument placements and recurring assay sales. Planned placements and UK manufacturing capacity create a structural revenue growth engine and product diversification that should increase long‑term consumables pull‑through.
Margin And Free-cash-flow Recovery Plan With Cost DisciplineManagement's multi‑pronged plan (cost actions, procurement, facility consolidation, working capital focus) plus clear targets for 23% adjusted EBITDA and $100–$120M free cash flow indicate structural steps to restore operating leverage and self‑funding ability, improving long‑term financial durability if executed.
Bears Say
Deteriorated Profitability And Negative Free Cash FlowA shift from multi‑year profitability to sizable net losses and negative free cash flow weakens the company's ability to internally fund growth or absorb shocks. Persistent operating losses erode reserves, constrain reinvestment in R&D and commercialization, and lengthen the path to sustainable profitability.
Elevated Leverage Reduces Balance-sheet FlexibilityHigher debt (debt/equity >1.5 and reported net debt/adjusted EBITDA ~4.1x) limits strategic optionality, increases interest and covenant risk, and raises refinancing exposure. This structurally reduces resilience to continued revenue weakness and constrains capital allocation priorities over coming quarters.
China Distributor Pause And Regulatory Pricing UncertaintyRegulatory-driven distributor pauses and draft national IVD pricing create structural demand uncertainty in a significant market. Potential pricing changes that affect roughly half of China sales can depress long‑term revenue and margin assumptions and complicate forecasting and investment decisions for the region.
QuidelOrtho News
QL1A FAQ
What was Quidelortho Corporation’s price range in the past 12 months?
Quidelortho Corporation lowest stock price was €8.22 and its highest was €30.40 in the past 12 months.
What is Quidelortho Corporation’s market cap?
Quidelortho Corporation’s market cap is €854.77M.
When is Quidelortho Corporation’s upcoming earnings report date?
Quidelortho Corporation’s upcoming earnings report date is Jul 30, 2026 which is in 51 days.
How were Quidelortho Corporation’s earnings last quarter?
Quidelortho Corporation released its earnings results on May 05, 2026. The company reported -€0.034 earnings per share for the quarter, missing the consensus estimate of €0.308 by -€0.342.
Is Quidelortho Corporation overvalued?
According to Wall Street analysts Quidelortho Corporation’s price is currently Undervalued.
Does Quidelortho Corporation pay dividends?
Quidelortho Corporation does not currently pay dividends.
What is Quidelortho Corporation’s EPS estimate?
Quidelortho Corporation’s EPS estimate is -0.02.
How many shares outstanding does Quidelortho Corporation have?
Quidelortho Corporation has 68,190,990 shares outstanding.
What happened to Quidelortho Corporation’s price movement after its last earnings report?
Quidelortho Corporation reported an EPS of -€0.034 in its last earnings report, missing expectations of €0.308. Following the earnings report the stock price went up 0.021%.
Which hedge fund is a major shareholder of Quidelortho Corporation?
Currently, no hedge funds are holding shares in DE:QL1A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
QuidelOrtho Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€10.44 (1.27% Upside)
€10.44 (1.27% Upside)
Blogger Sentiment
Bullish
DE:QL1A Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.07%
12-Months-Change
Fundamentals
Return on Equity
-56.31%
Trailing 12-Months
Asset Growth
-12.89%
Trailing 12-Months
Company Description
Quidelortho Corporation
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
QL1A Company Deck
QL1A Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: near-term headwinds were significant (a ~30% weaker respiratory season, an 8% decline in labs revenue, quarter-level margin and cash flow pressure, and China distributor pauses), but management emphasized strategic progress—completion of the Lex acquisition, new product launches (troponin, VITROS 450), cost actions, and a full-year plan targeting a 23% adjusted EBITDA margin and positive free cash flow of $100M–$120M. Given the company’s proactive mitigation steps, clear product and pipeline catalysts, and multi-pronged margin initiatives versus the material but largely contextual short-term revenue and cash setbacks, the tone is balanced between caution on near-term execution risks and optimism on medium-term recovery and margin improvement.View all DE:QL1A earnings summariesQL1A Stock 12 Month Forecast
Average Price Target
€10.44
▲(1.27% Upside)
Technical Analysis
Options Prices
Currently, No data available
---